This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Sutter, J. Articles by De Backer, G. Search for Related Content PubMed PubMed Citation Articles by De Sutter, J. Articles by De Backer, G.

Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients

Johan De Sutter, MD^*, Rene Tavernier, MD, PhD^*, Marc De Buyzere, PhD^*, Luc Jordaens, MD, PhD^* and Guy De Backer, MD, PhD, FACC

^* Departments of Department of Cardiology, the University Hospital Ghent, Ghent, Belgium
Department of Public Health of the University Hospital Ghent, Ghent, Belgium

View larger version (21K): [in a new window]   Figure 1 (A) Kaplan-Meier arrhythmia-free survival for the patients with and without lipid lowering drugs at discharge. (B) Kaplan-Meier cardiac death or hospitalization-free survival for the patients with and without lipid lowering drugs at discharge. ICD = internal cardioverter defibrillator; VF = ventricular fibrillation; VT = ventricular tachycardia.

View larger version (18K): [in a new window]   Figure 2 Kaplan-Meier arrhythmia-free survival for the patients on beta-blockers (n = 40) with and without lipid lowering drugs at discharge. VT = ventricular tachycardia; VF = ventricular fibrillation.

View larger version (18K): [in a new window]   Figure 3 (A) Total cholesterol values (mean ± SEM) for the patients with and without lipid lowering drugs at discharge and at the end of follow-up. **p < 0.01. (B) LDL cholesterol values (mean ± SEM) for the patients with and without lipid lowering drugs at discharge and at the end of the follow-up. **p < 0.01; *p < 0.05.